The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
Open accessPublished version of a preprint
Abstract
The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and therapeutics will depend on understanding viral immunity. We studied T cell memory in 42 patients following recovery from COVID-19 (28 with mild disease and 14 with severe disease) and 16 unexposed donors, using interferon-γ-based assays with peptides spanning SARS-CoV-2 except ORF1. The breadth and magnitude of T cell responses were significantly higher in severe as compared with mild cases. Total and spike-specific T cell responses correlated with spike-specific antibody responses. We identified 41 peptides containing CD4+ and/or CD8+ epitopes, including six immunodominant regions. Six optimized CD8+ epitopes were defined, with peptide-MHC pentamer-positive cells displaying the central and effector memory phenotype. In mild cases, higher proportions of SARS-CoV-2-specific CD8+ T cells were observed. The identification of T cell responses associated with milder disease will support an understanding of protective immunity and highlights the potential of including non-spike proteins within future COVID-19 vaccine design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using HLA class I and II predicted peptide “megapools,” circulating SARS-CoV-2-specific CD8+ and CD4+ T cells were identified in COVID-19 acute, mild and convalescent patients [110, 118-125].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [120]
Experimental — accuracy not yet measuredIn the citing paper
“By contrast, VAERD has not usually occurred if a TH1 cell-biased CD4+ T cell response is elicited, reflected by increased levels of interferon-γ (IFNγ), IL-2 and tumour necrosis factor (TNF)44–46,49.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [46]
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [40]
In the citing paper
“It should be noted that all plasma and sera tested completely inhibited entry at the lowest dilution tested and that T cell responses will contribute to control of SARS-CoV-2 infection, particularly in re-infected convalescent patients (Grifoni et al., 2020; Peng et al., 2020).”
From SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies (2021) · cites this paper as Peng et al., 2020
In the citing paper
“T cell responses are detected after almost all SARS-CoV-2 infections (Grifoni et al., 2020; Rydyznski Moderbacher et al., 2020; Peng et al., 2020; Sekine et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Peng et al., 2020
In the citing paper
“In SARS-CoV-2 infections, the presence of virus-specific CD8+ T cells has been associated with better COVID-19 outcomes (Rydyznski Moderbacher et al., 2020; Peng et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Peng et al., 2020
In the citing paper
“Current evidence suggests an early, robust, and diverse T cell response directed against SARS-CoV-2 correlates with milder COVID-19 outcomes126,131,132”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [132]
In the citing paper
“Severe COVID-19 has been associated with lower TCR diversity against SARS-CoV-2 epitopes131,132.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [132]
In the citing paper
“For CD8+ T cells, there are reports of diminished CD8+ cytotoxicity and cytokine production in severe cases126,132, while others report the opposite141, and still others find no differences142.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [132]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Self-citationCryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Coronaviruses: An Overview of Their Replication and Pathogenesis
Fehr, A. R., & Perlman, S. M. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2438-7_1 · Cited by 3,910
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa
Xu, H., Zhong, L., Deng, J., Peng, J., Dan, H., Zeng, X., Li, T., & Chen, Q. (2020) · International Journal of Oral Science · doi:10.1038/s41368-020-0074-x · Cited by 2,838
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19
Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X., Wang, F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0901-9 · Cited by 2,614
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00827 · Cited by 2,475
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Self-citation
Research works printed but not linked: 1
- Fehr, A. R. & Perlman, S. in Coronaviruses. Methods in Molecular Biology Vol. 1282 (eds Maier H., Bickerton E., Britton P.) 1–23 (Humana Press, 2015).
Cited by
Sorted by citations
Items 301–400 of 1,000
Pichler, D., Baumgartner, M. R., Kimpel, J., Rössler, A., Riepler, L., Bates, K., Fleischer, V., von Laer, D., Borena, W., & Würzner, R. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab300 · Cited by 39
Rowntree, L. C., Petersen, J., Juno, J. A., Chaurasia, P., Wragg, K. M., Koutsakos, M., Hensen, L., Wheatley, A. K., Kent, S. J., Rossjohn, J., et al. (2021) · Immunology and Cell Biology · doi:10.1111/imcb.12482 · Cited by 40
Jin, X., Ding, Y., Sun, S., Wang, X., Zhou, Z., Liu, X. K., Li, M., Chen, X., Shen, A., Wu, Y., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00784-8 · Cited by 39
Shaw, R. H., Liu, X., Stuart, A. S. V., Greenland, M., Aley, P. K., Andrews, N. J., Cameron, J. C., Charlton, S., Clutterbuck, E., Collins, A. M., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00163-1 · Cited by 38
Self-citationTarke, A., Ramezani-Rad, P., Neto, T. A. P., Lee, Y., Silva‐Moraes, V., Goodwin, B., Bloom, N. I., Siddiqui, L., Avalos, L., Frazier, A., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101583 · Cited by 38
Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects
Huynh, A., Arnold, D. M., Smith, J. W., Moore, J. C., Zhang, A., Chagla, Z., Harvey, B. J., Stacey, H. D., Ang, J. C., Clare, R., et al. (2021) · Viruses · doi:10.3390/v13040697 · Cited by 38
Volpatti, L. R., Wallace, R. P., Cao, S., Raczy, M. M., Wang, R., Gray, L. T., Alpar, A. T., Briquez, P. S., Mitrousis, N., Marchell, T. M., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00596 · Cited by 38
Anderson, R. M., Vegvari, C., Hollingsworth, T. D., Pi, L., Maddren, R., Ng, C. W., & Baggaley, R. F. (2021) · Interface Focus · doi:10.1098/rsfs.2021.0008 · Cited by 38
Combined assessment of MHC binding and antigen abundance improves T cell epitope predictions
Koşaloğlu‐Yalçın, Z., Lee, J., Greenbaum, J., Schoenberger, S. P., Miller, A. M., Kim, Y. J., Sette, A., Nielsen, M., & Peters, B. (2022) · iScience · doi:10.1016/j.isci.2022.103850 · Cited by 37
Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness
Tulimilli, S. V., Dallavalasa, S., Basavaraju, C. G., Rao, V. K., Chikkahonnaiah, P., Madhunapantula, S. V., & Veeranna, R. P. (2022) · Vaccines · doi:10.3390/vaccines10101751 · Cited by 39
Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients
Phadke, V. K., Scanlon, N., Jordan, S. C., & Rouphael, N. (2021) · Current Transplantation Reports · doi:10.1007/s40472-021-00322-5 · Cited by 38
Wang, P., Lau, S.-Y., Deng, S., Chen, P., Mok, B. W.-Y., Zhang, J., Lee, A. C.-Y., Chan, K., Tam, R. C.-Y., Xu, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23166-0 · Cited by 37
Alefishat, E. A., Jelinek, H. F., Mousa, M., Tay, G. K., & AlSafar, H. S. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.01.007 · Cited by 39
Furuyama, W., Shifflett, K., Pinski, A. N., Griffin, A. J., Feldmann, F., Okumura, A., Gourdine, T., Jankeel, A., Lovaglio, J., Hanley, P. W., et al. (2022) · mBio · doi:10.1128/mbio.03379-21 · Cited by 39
Divergent trajectories of antiviral memory after SARS-CoV-2 infection
Tomić, A., Skelly, D., Ogbe, A., O’Connor, D., Pace, M. J., Adland, E., Alexander, F., Ali, M., Allott, K., Ansari, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28898-1 · Cited by 35
Self-citationLin, J., Law, R., Korosec, C. S., Zhou, C. Y., Koh, W. H., Ghaemi, M. S., Samaan, P., Ooi, H. K., Matveev, V., Yue, F., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00509-22 · Cited by 38
Role of thymus in health and disease
Gulla, S., Reddy, M. C., Reddy, V. C., Chitta, S., Bhanoori, M., & Lomada, D. (2022) · International Reviews of Immunology · doi:10.1080/08830185.2022.2064461 · Cited by 39
Harris, P. E., Brasel, T., Massey, C., Herst, C. V., Burkholz, S., Lloyd, P. M., Blankenberg, T., Bey, T. M., Carback, R. T., Hodge, T. W., et al. (2021) · Vaccines · doi:10.3390/vaccines9050520 · Cited by 33
Pérez‐Martínez, A., Mora-Rillo, M., Ferreras, C., Guerra‐García, P., Pascual-Miguel, B., Mestre‐Durán, C., Borobia, A. M., Carcas, A. J., Queiruga‐Parada, J., Garcia, I., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101086 · Cited by 36
A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants
Pishesha, N., Harmand, T. J., Rothlauf, P. W., Praest, P., Alexander, R., van den Doel, R., Liebeskind, M. J., Vakaki, M. A., McCaul, N., Wijne, C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116147118 · Cited by 35
van der Ploeg, K., Kirosingh, A. S., Mori, D. A., Chakraborty, S., Hu, Z., Sievers, B. L., Jacobson, K. B., Bonilla, H. F., Parsonnet, J., Andrews, J. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100640 · Cited by 36
Högelin, K. A., Ruffin, N., Pin, E., Månberg, A., Hober, S., Gafvelin, G., Grönlund, H., Nilsson, P., Khademi, M., Olsson, T. P., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103078 · Cited by 34
Agrati, C., Castilletti, C., Goletti, D., Sacchi, A., Bordoni, V., Mariotti, D., Notari, S., Matusali, G., Meschi, S., Petrone, L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07741-z · Cited by 34
Altmann, D. M., Reynolds, C. J., Joy, G., Otter, A. D., Gibbons, J. M., Pade, C., Swadling, L., Maini, M. K., Brooks, T. J. G., Semper, A. E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40460-1 · Cited by 36
Cooper, R. S., Fraser, A. R., Smith, L. M., Burgoyne, P., Imlach, S. N., JARVIS, L. M., Turner, D. M., Zahra, S., Turner, M. L., & Campbell, J. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598402 · Cited by 33
Hamelin, D. J., Fournelle, D., Grenier, J., Schockaert, J., Kovalchik, K. A., Kubiniok, P., Mostefai, F., Duquette, J. D., Saab, F., Sirois, I., et al. (2021) · Cell Systems · doi:10.1016/j.cels.2021.09.013 · Cited by 35
Molodtsov, I. A., Kegeles, E., Mitin, A. N., Mityaeva, O. N., Musatova, O. E., Panova, A. E., Pashenkov, M. V., Peshkova, I. O., Alsalloum, A., Asaad, W., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac278 · Cited by 33
Becerra‐Artiles, A., Calvo‐Calle, J. M., Co, M. D. T., Nanaware, P. P., Cruz, J., Weaver, G. C., Lu, L., Forconi, C. S., Finberg, R. W., Moormann, A. M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110952 · Cited by 36
Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome
Lewnard, J. A., Hong, V. X., Kim, J. S., Shaw, S. F., Lewin, B. J., Takhar, H. S., & Tartof, S. Y. (2023) · Nature Communications · doi:10.1038/s41467-023-37051-5 · Cited by 33
Harrington, P., Doores, K. J., Saha, C., Saunders, J. G., Child, F. J., Dillon, R. J., Saglam, S., Raj, K. K., McLornan, D. P., Avenoso, D., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.002 · Cited by 34
Zhou, S., Zhang, R., You, Z.-W., Zou, Y.-K., Wen, Y., Wang, J., Ding, D., Bian, M.-M., Zhang, Z.-M., Yuan, H., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c19736 · Cited by 34
Aldea, M. D., Michot, J., Danlos, F., Ribas, A., & Soria, J. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0144 · Cited by 33
Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera
Vidal, S. J., Collier, A.-R. Y., Yu, J., McMahan, K., Tostanoski, L. H., Ventura, J. D., Aïd, M., Peter, L. E., Jacob-Dolan, C., Anioke, T., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00404-21 · Cited by 34
Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection
Yatim, N., Boussier, J., Tétu, P., Smith, N., Bruel, T., Charbit, B., Barnabei, L., Corneau, A., Meda, L. D., Allayous, C., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg4081 · Cited by 35
Nesterenko, P. A., McLaughlin, J., Tsai, B. L., Sojo, G. B., Cheng, D., Zhao, D. Y., Mao, Z., Bangayan, N. J., Obusan, M. B., Su, Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110167 · Cited by 33
Mutations in SARS-CoV-2 spike protein impair epitope-specific CD4+ T cell recognition
Tye, E. X. C., Jinks, E., Haigh, T. A., Kaul, B., Patel, P., Parry, H., Newby, M. L., Crispin, M., Kaur, N., Moss, P. A. H., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01351-7 · Cited by 37
BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy
McGee, M. C., August, A., & Huang, W. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5covr0620-306r · Cited by 33
Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection
Escudero-Pérez, B., Lawrence, P., & Castillo‐Olivares, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1156758 · Cited by 37
de Jesus, J. R., & Andrade, T. D. A. (2020) · Metallomics · doi:10.1039/d0mt00220h · Cited by 33
The Immune Response to SARS-CoV-2 and Variants of Concern
Torbati, E., Krause, K. L., & Ussher, J. E. (2021) · Viruses · doi:10.3390/v13101911 · Cited by 36
Johansson, A. M., Malhotra, U., Kim, Y. G., Gomez, R., Krist, M. P., Wald, A., Koelle, D. M., & Kwok, W. W. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010203 · Cited by 35
Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
Jeewandara, C., Aberathna, I. S., Pushpakumara, P. D., Kamaladasa, A., Guruge, D., Wijesinghe, A., Gunasekera, B., Ramu, S. T., Kuruppu, H., Ranasinghe, T., et al. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.621 · Cited by 55
Self-citationEvidence of previous SARS-CoV-2 infection in seronegative patients with long COVID
Krishna, B. A., Lim, E. Y., Mactavous, L., Lyons, P., Döffinger, R., Bradley, J. R., Smith, K. G. C., Sinclair, J. H., Matheson, N. J., Lehner, P. J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104129 · Cited by 32
Menges, D., Zens, K. D., Ballouz, T., Caduff, N., Llanas-Cornejo, D., Aschmann, H. E., Domenghino, A., Pellaton, C., Perreau, M., Fenwick, C. W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32573-w · Cited by 32
Ford, E. S., Mayer-Blackwell, K., Jing, L., Laing, K. J., Sholukh, A. M., Germain, R. S., Bossard, E. L., Xie, H. J., Pulliam, T. H., Jani, S., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01692-x · Cited by 34
Shimizu, K., Iyoda, T., Sanpei, A., Nakazato, H., Okada, M., Ueda, S., Kato-Murayama, M., Murayama, K., Shirouzu, M., Harada, N., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02885-6 · Cited by 33
Hassert, M., Geerling, E., Stone, E. T., Steffen, T. L., Feldman, M. S., Dickson, A. M., Class, J., Richner, J. M., Brien, J. D., & Pinto, A. K. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009163 · Cited by 30
Goenka, A., Halliday, A., Gregorová, M., Milodowski, E., Thomas, A. C., Williamson, M. K., Baum, H. E., Oliver, E., Long, A. E., Knežević, L., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100327 · Cited by 29
COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology
Neurath, M. F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00480-y · Cited by 30
Iannetta, M., Landi, D., Cola, G., Malagnino, V., Teti, E., Fraboni, D., Buccisano, F., Grelli, S., Coppola, L., Campogiani, L., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103157 · Cited by 32
Saba, A. A., Adiba, M., Saha, P., Hosen, M. I., Chakraborty, S., & Nabi, A. N. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104703 · Cited by 33
Redefining COVID-19 Severity and Prognosis: The Role of Clinical and Immunobiotypes
Torres-Ruiz, J. J., Pérez‐Fragoso, A., Maravillas‐Montero, J. L., Llorente, L., Mejía‐Domínguez, N. R., Páez-Franco, J. C., Romero‐Ramírez, S., Sosa‐Hernández, V. A., Cervantes‐Díaz, R., Absalón‐Aguilar, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689966 · Cited by 32
Zhang, B., Tian, J., Zhang, Q., Xie, Y., Wang, K., Qiu, S., Lu, K., & Liu, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.761173 · Cited by 36
Benet, S., Blanch-Lombarte, O., Ainsua‐Enrich, E., Pedreño-López, N., Muñoz‐Basagoiti, J., Regué, D. R., Perez‐Zsolt, D., Peña, R., Jímenez, E., de la Concepción, M. L. R., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac406 · Cited by 33
Hardy, N. J., Vegivinti, C. T. R., Mehta, M., Thurnham, J., Mebane, A., Pederson, J. M., Tarchand, R., Shivakumar, J., Olaniran, P., Gadodia, R., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01004-5 · Cited by 33
Antigenic variation of SARS‐CoV‐2 in response to immune pressure
Forni, D., Cagliani, R., Pontremoli, C., Mozzi, A., Pozzoli, U., Clerici, M., & Sironi, M. (2020) · Molecular Ecology · doi:10.1111/mec.15730 · Cited by 30
Cell‐mediated immunity to SARS‐CoV‐2
Wang, X., & Gui, J. (2020) · Pediatric Investigation · doi:10.1002/ped4.12228 · Cited by 32
Yang, J., Zhong, M., Zhang, E., Hong, K., Yang, Q., Zhou, D., Xia, J., Chen, Y.-Q., Sun, M., Zhao, B., et al. (2021) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjab014 · Cited by 32
Self-citationStankov, M. V., Cossmann, A., Bonifacius, A., Dopfer‐Jablonka, A., Ramos, G. M., Gödecke, N., Scharff, A. Z., Happle, C., Boeck, A.-L., Tran, A. T., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab555 · Cited by 31
Study of HLA-A, -B, -C, -DRB1 and -DQB1 polymorphisms in COVID-19 patients
Gutiérrez‐Bautista, J. F., Rodríguez-Nicolás, A., Rosales‐Castillo, A., López‐Ruz, M. Á., Martín-Casares, A. M., Fernández-Rubiales, A., Anderson, P. O., Garrido, F., Ruiz‐Cabello, F., & López‐Nevot, M. Á. (2021) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2021.08.009 · Cited by 36
Rapid Development of Analytical Methods for Evaluating Pandemic Vaccines: A Covid-19 Perspective
Baldwin, J., Piplani, S., Sakala, I. G., Honda‐Okubo, Y., Li, L., & Petrovsky, N. (2021) · Bioanalysis · doi:10.4155/bio-2021-0096 · Cited by 33
Mass spectrometric identification of immunogenic SARS-CoV-2 epitopes and cognate TCRs
Pan, K., Chiu, Y., Huang, E. L., Chen, M. M., Wang, J., Lai, I. P., Singh, S., Shaw, R., MacCoss, M. J., & Yee, C. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111815118 · Cited by 32
Chen, J., Wang, B., Caserto, J. S., Shariati, K., Cao, P., Pan, Y., Xu, Q., & Ma, M. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101714 · Cited by 30
Self-citationCD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives
Mortezaee, K., & Majidpoor, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864298 · Cited by 34
Post-vaccination T cell immunity to omicron
Jacobsen, H., Jiménez, V. C., Sitaras, I., Bar‐Zeev, N., Čičin‐Šain, L., Higdon, M. M., & Knoll, M. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944713 · Cited by 30
Non-infectious status indicated by detectable IgG antibody to SARS-CoV-2
Denning, D. W., Kilcoyne, A., & Ucer, C. (2020) · BDJ · doi:10.1038/s41415-020-2228-9 · Cited by 30
SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges
Wellens, J., Colombel, J., Satsangi, J. J., & Wong, S.-Y. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab046 · Cited by 30
Taus, E., Hofmann, C., Ibarrondo, F. J., Hausner, M. A., Fulcher, J. A., Krogstad, P. A., Ferbas, K. G., Tobin, N. H., Rimoin, A. W., Aldrovandi, G. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835830 · Cited by 31
Cassaniti, I., Gregorini, M., Bergami, F., Arena, F., Sammartino, J. C., Percivalle, E., Soleymaninejadian, E., Abelli, M., Ticozzelli, E., Nocco, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10060921 · Cited by 30
Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice
Alves, R. P. D. S., Timis, J., Miller, R., Valentine, K. M., Pinto, P. B. A., Gonzalez, A., Regla-Nava, J. Á., Maule, E., Nguyen, M. N., Shafee, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45043-2 · Cited by 29
Potential immune evasion of the severe acute respiratory syndrome coronavirus 2 Omicron variants
Chen, L., He, Y., Liu, H., Shang, Y., & Guo, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1339660 · Cited by 32
T cell phenotypes in COVID-19 - a living review
Hanna, S. J., Codd, A. S., Gea‐Mallorquí, E., Scourfield, D. O., Richter, F. C., Ladell, K., Borsa, M., Compeer, E. B., Moon, O. R., Galloway, S. A. E., et al. (2020) · Oxford Open Immunology · doi:10.1093/oxfimm/iqaa007 · Cited by 29
Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection
Ameratunga, R., Woon, S., Jordan, A., Longhurst, H. J., Leung, E. Y., Steele, R. H., Lehnert, K., Snell, R. G., & Brooks, A. E. S. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1905525 · Cited by 28
Matyushenko, V., Isakova–Sivak, I., Kudryavtsev, I. V., Goshina, A., Chistyakova, A. K., Stepanova, E., Prokopenko, P., Sychev, I. А., & Георгиевна, Р. Л. (2021) · Viruses · doi:10.3390/v13081490 · Cited by 31
Longitudinal analysis of antibody decay in convalescent COVID-19 patients
Xia, W., Li, M., Wang, Y., Kazis, L. E., Berlo, K., Melikechi, N., & Chiklis, G. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-96171-4 · Cited by 32
Quiros‐Fernandez, I., Poorebrahim, M., Fakhr, E., & Arregui, A. C. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103610 · Cited by 32
Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine
Coléon, S., Wiedemann, A., Surénaud, M., Lacabaratz, C., Hüe, S., Prague, M., Cervantes-Gonzalez, M., Wang, Z., Ellis, J., Sansoni, A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104062 · Cited by 29
The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognition
Motozono, C., Toyoda, M., Tan, T. S., Hamana, H., Goto, Y., Aritsu, Y., Miyashita, Y., Oshiumi, H., Nakamura, K., Okada, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33068-4 · Cited by 31
CD8+ T-cell immune escape by SARS-CoV-2 variants of concern
Kombe, A. J. K., Biteghe, F. A. N., Ndoutoume, Z. N., & Jin, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.962079 · Cited by 29
Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives
Zhu, Q., Xu, Y., Wang, T., & Xie, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1053437 · Cited by 32
Jacobsen, E., Fabricius, D., Class, M., Topfstedt, F., Lorenzetti, R., Janowska, I., Schmidt, F., Staniek, J., Zernickel, M., Stamminger, T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35055-1 · Cited by 29
HLA Variation and SARS-CoV-2 Specific Antibody Response
Wolday, D., Fung, C. Y. J., Morgan, G., Casalino, S., Frangione, E., Taher, J., & Lerner‐Ellis, J. P. (2023) · Viruses · doi:10.3390/v15040906 · Cited by 31
Innate and adaptive immunity to SARS-CoV-2 and predisposing factors
Shen, J., Fan, J., Zhao, Y., Jiang, D., Niu, Z., Zhang, Z., & Cao, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1159326 · Cited by 38
Self-citationReactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology
Steiner, S., Schwarz, T., Corman, V. M., Sotzny, F., Bauer, S., Drosten, C., Volk, H., Scheibenbogen, C., & Hanitsch, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687449 · Cited by 29
Binayke, A., Zaheer, A., Vishwakarma, S., Singh, S., Sharma, P., Chandwaskar, R., Gosain, M., Raghavan, S., Murugesan, D. R., Kshetrapal, P., et al. (2024) · npj Vaccines · doi:10.1038/s41541-023-00794-9 · Cited by 28
COVID-19: The Emerging Immunopathological Determinants for Recovery or Death
Ahmad, T., Chaudhuri, R., Joshi, M. C., Almatroudi, A., Rahmani, A. H., & Ali, S. M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.588409 · Cited by 30
Nanobased Platforms for Diagnosis and Treatment of COVID-19: From Benchtop to Bedside
Bidram, E., Esmaeili, Y., Amini, A., Sartorius, R., Tay, F. R., Shariati, L., & Makvandi, P. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00318 · Cited by 27
Immunological Profiling of COVID-19 Patients with Pulmonary Sequelae
Wu, J., Tang, L., Ma, Y., Li, Y., Zhang, D., Li, Q., Mei, H., & Hu, Y. (2021) · mBio · doi:10.1128/mbio.01599-21 · Cited by 30
Effective chimeric antigen receptor T cells against SARS-CoV-2
Guo, X., Kazanova, A., Thurmond, S., Saragovi, H. U., & Rudd, C. E. (2021) · iScience · doi:10.1016/j.isci.2021.103295 · Cited by 29
Peng, H. T., Rhind, S. G., & Beckett, A. (2021) · JMIR Public Health and Surveillance · doi:10.2196/25500 · Cited by 29
The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines
Sun, Z., Wu, T., Xie, H., Li, Y., Zhang, J., Su, X., & Qi, H. (2022) · Vaccines · doi:10.3390/vaccines10071103 · Cited by 29
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIVPreprint
Alrubayyi, A., Gea‐Mallorquí, E., Touizer, E., Hameiri‐Bowen, D., Kopycinski, J. T., Charlton, B. G., Fisher-Pearson, N., Muir, L., Rosa, A., Roustan, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.15.431215 · Cited by 28
Self-citationLaw, J. C., Koh, W. H., Budylowski, P., Lin, J., Yue, F., Abe, K. T., Rathod, B., Girard, M., Li, Z., Rini, J. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2001067 · Cited by 27
The presentation of SARS-CoV-2 peptides by the common HLA-A∗02:01 molecule
Szeto, C. W., Chatzileontiadou, D. S. M., Nguyen, A., Sloane, H., Lobos, C. A., Jayasinghe, D., Halim, H., Smith, C., Riboldi‐Tunnicliffe, A., Grant, E. J., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102096 · Cited by 27
Age, Disease Severity and Ethnicity Influence Humoral Responses in a Multi-Ethnic COVID-19 Cohort
Smith, M., Abdesselem, H., Mullins, M. O., Tan, T.-M., Nel, A. J. M., Al‐Nesf, M. A., Bensmail, I., Majbour, N. K., Vaikath, N. N., Naik, A., et al. (2021) · Viruses · doi:10.3390/v13050786 · Cited by 27
Infection and Immune Memory: Variables in Robust Protection by Vaccines Against SARS-CoV-2
Ahluwalia, P. K., Vaibhav, K., Ahluwalia, M., Mondal, A. K., Sahajpal, N., Rojiani, A. M., & Kolhe, R. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660019 · Cited by 25
Lehmann, A. A., Kirchenbaum, G. A., Zhang, T., Reche, P. A., & Lehmann, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635942 · Cited by 27
Impaired Priming of SARS-CoV-2-Specific Naive CD8+ T Cells in Older Subjects
Gallerani, E., Proietto, D., Dallan, B., Campagnaro, M., Pacifico, S., Albanese, V., Marzola, E., Marconi, P., Caputo, A., Appay, V., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693054 · Cited by 28
Boshier, F. A. T., Pang, J., Penner, J., Hughes, J., Parker, M. D., Shepherd, J., Alders, N., Bamford, A., Grandjean, L., Grünewald, S., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27285 · Cited by 27
Metadata
- Authors
- Peng, Y., Mentzer, A. J., Liu, G., Yao, X., Yin, Z., Dong, D., Dejnirattisai, W., Rostron, T., Supasa, P., Liu, C., López-Camacho, C., Slon-Campos, J., Zhao, Y., Stuart, D. I., Paesen, G. C., Grimes, J. M., Antson, A. A., Bayfield, O. W., Hawkins, D. E. D. P., Ker, D.-S., Wang, B., Turtle, L., Subramaniam, K., Thomson, P., Zhang, P., Dold, C., Ratcliff, J., Simmonds, P., de Silva, T., Sopp, P., Wellington, D., Rajapaksa, U., Chen, Y.-L., Salio, M., Napolitani, G., Paes, W., Borrow, P., Kessler, B. M., Fry, J. W., Schwabe, N. F., Semple, M. G., Baillie, J. K., Moore, S. C., Openshaw, P. J. M., Ansari, M. A., Dunachie, S., Barnes, E., Frater, J., Kerr, G., Goulder, P., Lockett, T., Levin, R., Zhang, Y., Jing, R., Ho, L.-P., Oxford Immunology Network Covid-19 Response T cell Consortium, Barnes, E., Dong, D., Dong, T., Dunachie, S., Frater, J., Goulder, P., Kerr, G., Klenerman, P., Liu, G., McMichael, A., Napolitani, G., Ogg, G., Peng, Y., Salio, M., Yao, X., Yin, Z., ISARIC4C Investigators, Kenneth Baillie, J., Klenerman, P., Mentzer, A. J., Moore, S. C., Openshaw, P. J. M., Semple, M. G., Stuart, D. I., Turtle, L., Cornall, R. J., Conlon, C. P., Klenerman, P., Screaton, G. R., Mongkolsapaya, J., McMichael, A., Knight, J. C., Ogg, G., & Dong, T.
- Affiliations
- University of Oxford (GB)
- Centre for Human Genetics (GB)
- University of York (GB)
- University of Liverpool (GB)
- University of Sheffield (GB)
- ProImmune (United Kingdom) (GB)
- Oxford University Hospitals NHS Trust (GB)
- Worthing Hospital (GB)
- Capital Medical University (CN)
- University of Edinburgh (GB)
- Siriraj Hospital (TH)
- ORCID
- Dejnirattisai, Wanwisa
- Supasa, Piyada
- Liu, Chang
- López-Camacho, César
- Slon-Campos, Jose
- Zhao, Yuguang
- Paesen, Guido C.
- Grimes, Jonathan M.
- Antson, Alfred A.
- Bayfield, Oliver W.
- Hawkins, Dorothy E. D. P.
- Ker, De-Sheng
- Wang, Beibei
- Subramaniam, Krishanthi
- Thomson, Paul
- Zhang, Ping
- Dold, Christina
- Ratcliff, Jeremy
- Simmonds, Peter
- de Silva, Thushan
- Wellington, Dannielle
- Rajapaksa, Ushani
- Chen, Yi-Ling
- Paes, Wayne
- Borrow, Persephone
- Kessler, Benedikt M.
- Fry, Jeremy W.
- Ansari, M. Azim
- Zhang, Yonghong
- Ho, Ling-Pei
- Cornall, Richard J.
- Screaton, Gavin R.
- Mongkolsapaya, Juthathip
- Knight, Julian C.
- Venue
- Nature Immunology
- Published
- 2020-09-04
- Volume
- 21
- Issue
- 11
- Pages
- 1336-1345
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- PMC
- PMC7611020
- OpenAlex
- W3082438395
- Cited by
- 1,179
- References
- 42
- Citations by year
- 2026: 41 · 2025: 68 · 2024: 118 · 2023: 171 · 2022: 291 · 2021: 398 · 2020: 91
- FWCI
- 30.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature Immunology (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Oxford University Research Archive (ORA) (University of Oxford) (acceptedVersion)
- PubMed Central (submittedVersion)
- Funders
- RCUK | Medical Research Council (MC_PC_19059)
- Chinese Academy of Medical Sciences (2018-I2M-2-002)
- China Scholarship Council
- Wellcome Trust (205228/Z/16/Z, 110058/Z/15/Z, 215091/Z/18/Z, 095541/A/11/Z, award 206377 to AAA)
- DH | NIHR | Health Services Research Programme (NIHR200907, CO-CIN-01)
- University of Liverpool
- University of Oxford
- University of Edinburgh
- DH | National Institute for Health Research (NIHR200927 /WHRG_P82523, NIHR201385 / WHRR P84026, NIHR200907)
- Imperial College London (IS-BRC-1215-20013)
- Worthing Hospital
- Oxford University Hospitals NHS Trust
- National Institutes of Health, National Key R&D Program of China
- University of York
- ProImmune Ltd
- Bill and Melinda Gates Foundation (MC_PC_19059)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- SARS-CoV-2, COVID-19 pandemic, T cell memory, CD4+ T cells, CD8+ T cells, epitope mapping, immunodominant epitopes, spike protein, disease severity, convalescent patients, central memory T cells, effector memory T cells, antiviral immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
